Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Kindred Raises Offer for Gentiva Matching Unknown Bidder

July 21 (Bloomberg) -- Kindred Healthcare Inc., a long-term medical care provider, raised its bid for Gentiva Health Services Inc., adding fuel to a bidding war for the home-care and hospice company.

Kindred offered $17.25 a share, the company said in a letter today to Gentiva’s board, matching the amount proposed by an unnamed bidder that Gentiva announced on July 17. Based on Gentiva’s 36.8 million outstanding shares, the value of the deal would be $634.8 million.

“We have been clear that we are willing to consider further increasing our offer if you engage in good faith and permit us to conduct due diligence,” Kindred Chief Executive Officer Paul Diaz wrote in the letter, adding that the offer was contingent on Gentiva engaging in talks.

Formation Capital LLC, a closely held private equity firm that specializes in senior housing, is the mystery bidder, Bloomberg First Word reported, citing a person familiar with the matter.

“We have indicated our willingness to structure a transaction so that Gentiva shareholders can receive all cash or a mix of cash and stock, which would allow them to participate in the combined company’s substantial upside potential,” Diaz wrote in the letter to Gentiva.

Gentiva shares rose less than 1 percent to $18 in extended trading at 5:32 p.m. New York time after closing at $17.95. The company has gained 72 percent in the past 12 months.

Previous Offer

Louisville, Kentucky-based Kindred offered on July 14 to buy a 14.9 percent stake in Gentiva for $16 a share after the company rejected two takeover bids, a change in strategy to try and force the company to enter talks. That’s the most Kindred can buy without triggering a “poison pill” takeover defense by Atlanta-based Gentiva.

Gentiva turned down a June offer from Kindred of $14.50 a share for the company, valued at $573 million, and an offer of $14 a share, or about $533 million, announced May 15.

Gentiva has received Kindred’s latest offer and the board “in consultation with its financial and legal advisers, will review the proposal carefully in due course,” the company said in a statement.

Nick Lamplough, a spokesman for Kindred, declined to comment on the increased offer.

Calls to Formation Capital and to CEO Brian Beckwith weren’t immediately returned.

To contact the reporters on this story: Caroline Chen in New York at cchen509@bloomberg.net; Marie French in New York at mfrench25@bloomberg.net

To contact the editors responsible for this story: Reg Gale at rgale5@bloomberg.net Andrew Pollack, Ben Livesey

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.